Oscar Health Inc Stock Price, News & Analysis

Oscar Health (NYSE: OSCR) announced 2026 individual-market expansions and new member features for open enrollment starting Nov. 1, 2025 for certain groups. The Oscar experience will be offered in 573 counties across 20 states, including new entry into Alabama and Mississippi.

Key product launches include Oswell, a personal AI agent powered by OpenAI that accesses records, benefits, and care guides to assist members and connect them to $0 virtual care; HelloMeno, a menopause plan with $0 primary, gyne, and behavioral visits and estimated savings of ~$900/year; and expanded clinical plans for chronic conditions with estimated savings of ~$800/year. Oscar also introduced a digital rewards program, Hola Oscar for Hispanic and Latino members, and the Hy-Vee Health with Oscar employer plan in Des Moines.

Oscar Health (NYSE: OSCR) will release its Q3 2025 financial results before the market opens on Thursday, November 6, 2025. Management will discuss results on a conference call starting at 8:00 AM ET.

Investors can join by phone at 1.855.761.5600 (Conference ID: 7768132) or listen via webcast. The webcast will be archived on the company's investor relations site for 90 days after November 6, 2025.

Oscar Health (NYSE:OSCR) has successfully priced an upsized offering of $355 million in convertible senior subordinated notes due 2030, with a 2.25% interest rate. The offering, increased from the initially announced $350 million, includes an option for purchasers to buy an additional $55 million in notes.

The notes will convert at an initial rate of 40.2946 shares per $1,000 principal amount, representing a conversion price of $24.82 per share - a 32.5% premium over the last closing price. To mitigate dilution, Oscar entered into capped call transactions with a cap price of $37.46 per share.

Net proceeds of approximately $342.5 million will support general corporate purposes, including AI initiatives, healthcare experience enhancement, and potential premium tax credit extensions. The company will also terminate its existing revolving credit facility upon the offering's closing.

Oscar Health (NYSE:OSCR) has announced plans to offer $350 million in convertible senior subordinated notes due 2030, with an additional option for purchasers to buy up to $52.5 million in notes. The offering aims to support general corporate purposes, including AI initiatives, healthcare cost reduction, and enhanced consumer experiences.

The notes will be convertible to cash, class A common stock, or a combination thereof. To mitigate potential dilution, Oscar will enter into capped call transactions. The company plans to terminate its existing revolving credit facility upon the offering's closing. The notes will be redeemable after September 6, 2028, if Oscar's stock price exceeds 130% of the conversion price for a specified period.

Oscar Health (NYSE:OSCR) and Hy-Vee have announced a strategic partnership to launch Hy-Vee Health with Oscar, an innovative employer healthcare benefit program. The initiative will debut in Des Moines, Iowa, targeting approximately 400,000 employees through the individual marketplace starting November 1, 2025.

The program offers significant cost savings, with businesses potentially saving 20% to 30% and employees saving $500 to $1,000 annually. Key benefits include $0 care at Hy-Vee Health Exemplar Care clinics, access to MercyOne specialists, affordable prescriptions at Hy-Vee pharmacies, dedicated Oscar Care Guides, and Hy-Vee rewards for grocery savings.

Oscar Health (NYSE:OSCR) reported its Q2 2025 financial results, showing significant revenue growth but facing profitability challenges. Total revenue reached $2.9 billion, up from $2.2 billion in Q2 2024, driven by increased membership to 2.02 million members.

The company reported a net loss of $228.4 million ($0.89 per share) compared to a net income of $56.2 million in Q2 2024. The medical loss ratio increased to 91.1% from 79.0%, while the SG&A expense ratio improved to 18.7% from 19.6%. Management expects market stabilization in 2026 and anticipates a return to profitability, viewing the individual market as having long-term growth potential.

Oscar Health (NYSE:OSCR) released preliminary Q2 2025 results and revised its 2025 guidance downward. The company expects a Q2 2025 operating loss of $230 million and a net loss of $228 million. The revision follows analysis of 2025 Marketplace data showing higher-than-expected ACA Marketplace risk scores.

For full year 2025, Oscar now projects total revenue of $12.0-12.2 billion, a medical loss ratio of 86.0-87.0%, and an SG&A expense ratio of 17.1-17.6%. The company anticipates a loss from operations between $300 million and $200 million. In response, Oscar plans to resubmit 2026 rate filings for approximately 98% of current membership to reflect higher market risk scores.

Oscar Health reported robust Q1 2025 financial results with significant growth across key metrics. Total revenue surged 42% year-over-year to $3.0 billion, driven by increased membership. Net income reached $275.3 million ($0.92 per diluted share), up from $177.4 million in Q1 2024. The company's total membership grew to 2.04 million, primarily in Individual and Small Group segments. Operating efficiency improved with SG&A ratio decreasing to 15.8% from 18.4%, while medical loss ratio slightly increased to 75.4%. Adjusted EBITDA rose to $328.8 million, reflecting strong operational performance. The company reaffirmed its full-year 2025 guidance across all metrics.

Oscar Health (NYSE: OSCR), a healthcare technology company, has scheduled its first quarter 2025 financial results release and earnings conference call. The company will announce Q1 2025 results before market opening on Wednesday, May 7, 2025, followed by a management conference call at 8:00 AM ET.

Investors can access the call via phone at 1.855.761.5600 (Conference ID: 7768132) or through webcast. The call recording will be available on Oscar's investor relations website (ir.hioscar.com) for 90 days after the event.